SEC EDGARSEP 181 min read$CBIO

Bispham Barbara Harlin sold $11K of CBIO

Bispham Barbara Harlin (See Remarks) sold 620 shares of CRESCENT BIOPHARMA, INC. (CBIO) at $17.90 on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Bispham Barbara Harlin

Published Sep 18, 2026, 8:02 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 18, 2026, 8:42 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$CBIO

Neutral

high confidence

Mentioned

$CBIO

Relevance

2/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CBIONeutralLow

Why it matters

The transaction is routine and unlikely to affect CBIO's stock price.

Market read

Low relevance; typical insider transaction with minimal market impact.

What to watch

Potential upcoming dilution or financing events not disclosed.

Relevance 2/10Novelty 4/10Timing: filed 2026-09-18

Background

SEC Form 4 filing reports an insider's open‑market sale under a pre‑arranged plan.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CBIONeutralHigh confidence

Context

Officer Bispham Barbara Harlin sold 620 shares for $11,098 via a 10b5‑1 plan, reducing her stake to 18,710 shares.

Expected impact

No significant impact; price may stay flat.

Evidence & confidence

The sale size is small relative to market cap and disclosed via a routine 10b5‑1 plan.

Market effects

Sector

None; biotech sector unchanged.

Regional

None; US market unaffected.

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; monitor for further disposals.

Key entities

Company
Crescent Biopharma, Inc.
Biopharma company listed on NASDAQ under ticker CBIO.
Officer
Bispham Barbara Harlin
Company officer executing a 10b5‑1 sale.

Read at source ← All news

JUL 30

$CBIOMed

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treate

SEC EDGAR 8-K4 min

JUL 20

$CBIOLowAI 8/10

Fairmount Funds Management LLC purchased $12.4M of CBIO (indirect holdings)

Fairmount Funds Management LLC purchased 853,450 indirectly-held shares of CRESCENT BIOPHARMA, INC. (CBIO) at $14.50 ($12.38M total) on 2026-07-16.

SEC EDGAR2 min

JUL 15

$CBIOMedAI 8/10

Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

Crescent Biopharma (Nasdaq: CBIO) priced an underwritten public offering of 8,094,793 ordinary shares and pre-funded warrants for up to 525,897 shares. The share price was $14.50, and gross proceeds are expected at about $125.0 million before fees. A 30-day option allows underwriters to buy 1,293,103 more shares. Closing is expected July 16, 2026.

manilatimes.net4 min

JUL 14

$CBIOMed

Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

Crescent Biopharma (Nasdaq: CBIO) began an underwritten public offering of ordinary shares, or pre-funded warrants in lieu of shares, under an SEC shelf registration effective July 10, 2026. The underwriters may buy an additional 15% of shares within 30 days. Jefferies, TD Cowen, Guggenheim and Cantor are joint managers.

manilatimes.net2 min

JUL 14

$CBIOLow

CRESCENT BIOPHARMA, INC. (CBIO): Results of Operations and Financial Condition

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. cbio-20260714 0001253689 false 0001253689 2026-07-14 2026-07-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________________________________________________ FORM 8-K ______________________________________

SEC EDGAR 8-K1 min

OCT 2

$DBRGMed

Ganzi Marc C sold (to issuer) $44.5M of DBRG

Ganzi Marc C (CEO) sold (to issuer) 2,779,201 shares of DigitalBridge Group, Inc. (DBRG) at $16.00 ($44.47M total) on 2026-09-30.

SEC EDGAR1 min